TQ Quiz | Retinal and OCT Grand Rounds (Phoenix 2023) by Events@optometricedu.com | Apr 17, 2023 | 2023 Phoenix, TQ Courses | 0 comments "*" indicates required fields HiddenRetinal and OCT Grand RoundsHiddenDate (Hidden) MM slash DD slash YYYY HiddenEvent Date (Hidden) MM slash DD slash YYYY HiddenEvent 60 days past date (Hidden) MM slash DD slash YYYY HiddenEvent Date Difference (Hidden)1. Which of the following is NOT TRUE regarding OCT-Angiography* A - No dye is needed B - Structure and function can be displayed on one system C - Potentially more readily available in the optometric setting D - Takes longer to perform than traditional FA 2. One disadvantage of OCTA is* A - Lack of published studies B - Lack of acceptance in eye care community C - Inability to view periphery D - Cost of needed supplies 3. OCT-Angiography may be useful in the following clinical entities EXCEPT* A - Observing dry AMD for conversion to wet B - Monitoring diabetic patients C - Identifying CNVM in CSR patients D - Peripheral neovascularization 4. OCTA may not be useful in which entity?* A - AMD B - Diabetic retinopathy C - CME D - Vein occlusion 5. All of the following companies have a commercially available OCTA unit in the United States EXCEPT:* A - Optos B - Heidelberg C - Optovue D - Zeiss 6. Which of the following layer of the retina is AVASCULAR and thus should not have any vessels, unless there is an underlying disease process?* A - Superficial capillary plexus B - Deep capillary plexus C - Outer retinal zone D - Choriocapillaris 7. The majority of changes seen in diabetic retinopathy with OCTA will be most evident in which two layers?* A - Superficial capillary plexus and deep capillary plexus B - Deep capillary plexus and outer retinal zone C - Outer retinal zone and superficial capillary plexus D - Choriocapillaris and deep capillary plexus 8. OCT-A is MOST useful in patients with diabetes to look for* A - Diabetic macula edema B - Macular ischemia C - Neovascularization elsewhere (NVE) D - Neovascularization of the disc (NVD) 9. OCTA may be useful in glaucoma to* A - Look at changes in ONH flow and perfusion over time B - Evaluate the c/d ratio more accurately C - Determine damage to the ganglion cell complex D - Evaluate rim defects more closely 10. In regards to AMD, OCTA may be useful for the following EXCEPT* A - Locate small CNVMs as soon as possible to get prompt treatment B - Differentiate from similar conditions that my look the same C - Track changes in size to see if therapy is working D - Predict a patients response to therapy 11. The most common cause of a macula hole is* A - Blunt trauma B - Severe myopia C - Following CME D - Idiopathic, including vitreous traction 12. What is the vision typically with a full thickness macular hole* A - 20/20 B - 20/40 C - 20/200 D - Counting fingers 13. Which of the following regarding lamellar macula holes is TRUE?* A - Vision is typically 20/200 or worse B - Surgery is always indicated C - They tend to be relatively stable and slowly progressive D - All layers of the retina are missing, including the photoreceptor layer 14. Which of the following statements regarding VMT (vitreomacular traction) is TRUE?* A - It is very easy to diagnose without OCT B - Aphakia and pseudophakia are risk factors for the development of VMT C - With the advent of OCT, it is much more commonly encountered than previously thought D - It is most common in middle aged men 15. The incidence of ERMs after the age of 70 is approximately* A - 1% B - 10% C - 50% D - 95% 16. Which of the following is NOT a risk factor for CSR?* A - Type A personality B - Race C - Stress D - Use of systemic corticosteroids 17. Additional risk factors for CSR may include the following EXCEPT:* A - Sleep apnea B - Viagra use C - Increased choroidal thickness D - Refractive error 18. The classic FA appearance of CSR is described as* A - Petalloid B - Smoke-stack C - Ink blot D - Featureless 19. Which of the following statements regarding CSR is TRUE?* A - Presenting acuity is typically 20/200 or worse B - Recurrence is unlikely C - CNVM is a common side effect D - 80-90% of patients resolve to normal or near normal acuity within 1-6 months 20. Choroidal thickness may play a role in which disease process?* A - Central Serous Retinopathy B - Geographic Atrophy C - Polypoidal choroidopathy D - All of the above Personal InformationName* First Last Email* Phone*OE Tracker # License # Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationPromotional Code Retinal and OCT Grand Rounds | TQ Credit*After 6/16/2023, pricing will increase to $30. Price: (Past 60 Days) Retinal and OCT Grand Rounds | TQ CreditThis course was presented over 60 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: Promotional Discount Price: (Past 60 Days) Retake Discount Price: (Past 60 Days) Promotional Discount Price: Paying Via Credit Card A Paypal account is not required to pay using the button below. To pay using a credit card, click the Paypal button below. A new window will appear and a button "Pay with Debit or Credit Card" is available at the bottom of that window for your convenience. Payment MethodPayPal Checkout MasterCardVisaSupported Credit Cards: MasterCard, Visa Card Number Expiration Date Security Code Cardholder Name HiddenCourse Information (HIDDEN)HiddenCourse Name (HIDDEN) HiddenRetake Code (HIDDEN) HiddenQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/) HiddenCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
